相关实验视频

Updated: Sep 12, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

用[99m]Tc检测前列腺癌Tc-HYNIC-iPSMA SPECT:澳大利亚的经验

G Currie¹, P Tually², L Groombridge³

¹Charles Sturt University, Wagga Wagga, Australia.

Radiography (London, England : 1995)

|August 5, 2025

概括

-99m-HYNIC-PSMA SPECT成像是一种安全有效的前列腺癌 (PrCa) 检测替代方案,特别是在偏远地区. 这种分子成像方法在PET/CT无法访问的41%的病例中改善了患者管理.

科学领域:

核医学是一种核医学.
分子成像学分子成像学
放射性药物放射性药物放射性药物

背景情况:

在前列腺癌 (PrCa) 检测和分期方面,Tc-HYNIC-iPSMA SPECT/CT为PET/CT提供了一个潜在的替代方案.
它解决了获得先进分子成像技术的限制,特别是针对农村和社会经济弱势群体.
这项研究评估了Tc-HYNIC-iPSMA SPECT在偏远西澳大利亚PrCa患者的安全性和临床影响.

研究的目的:

评估Tc-HYNIC-iPSMA SPECT成像在前列腺癌患者队列中的安全性和临床实用性.
确定这种成像模式是否可以提高诊断能力,并影响资源有限的环境中的患者管理.

主要方法:

一项前性观察性研究,涉及27名西澳大利亚农村的前列腺癌确诊患者.
患者接受了静脉注射99mTc-HYNIC-iPSMA (650-800 MBq),然后在注射后2-4小时进行平面全身,静态和SPECT/CT成像 (胸部,腹部,骨盆).
对不良事件进行了监测,并从医疗记录中收集了患者随访数据.

主要成果:

在任何患者中都没有报告与治疗相关的不良事件,这表明了有利的安全性.
在96.3%的患者中观察到正常的生理生物分布,平均放射性化学纯度为92.5%.
在81.5%的患者中,Tc-HYNIC-iPSMA检测到至少一个PSMA阳性病变,并且在40.7%的病例中发现改变了治疗方法.

结论:

99m Tc-HYNIC-iPSMA SPECT成像是前列腺癌可靠的替代成像方式,提高了诊断准确性和患者管理.
这种方法显著影响了PET/CT无法进入的环境中的患者护理,解决了地理和社会经济障碍.
这项研究支持Tc-HYNIC-iPSMA作为一种工具,通过改善分子成像访问来缩小前列腺癌护理中的公平差距.

关键词:

在99mTc-HYNIC-PSMA中使用.在PSMA上,PSMA可以在PSMA上进行交易.前列腺癌是什么意思前列腺癌是什么意思在SPECT/CT测试中,Tc-99m-iPSMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMA Tc-99m-iPSMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMA

更多相关视频

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

相关概念视频

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...